Catalent, Inc. (CTLT) – Operational Challenges affect productivity

This report is useful for M&A, business & investment analysis to all students, researchers, investors, private equity houses, broking firms, hedge funds, advisory firms and corporates to decide upon their investment strategies. Do connect with us, if you are looking for equity valuation, recommendation, analysis and market recommendation for any specific company, sector and industry.

Catalent, Inc. (CTLT) (Q2FY23)

Highlights

Catalent revenue decreased $26mn, or 2% in Q2FY23, excluding the impact of foreign exchange, compared to Q2FY22. Net revenue increased by $19mn, or 1% in 1HFY23, excluding the impact of foreign exchange, compared to 1HFY22.

We believe that the company need to resize its costs to adapt to the lower level of revenue. This will help boost the company’s margin and performance. We believe that the strong growth in Biologics will help the company in long term.

Valuation

– Enterprise Value
– CrispIdea Forecast
– CrispIdea Segment Forecast
– Economic Value Added Analysis
– Discounted Cash Flow Analysis
– PE Band Comparison
– Peer Valuation
– CrispIdea Forecast Relative to Consensus
– Consensus History and Surprise
– Consensus Momentum

Actual & Historical Performance

– Income Statement
– Balance Sheet
– Cash Flow
– 10 Year Historical Performance
– Ratio Analysis
– Du Pont Analysis
– ROIC & ROCE Analysis
– Segment Performance

Peer Performance

– Summary
– Profitability
– Growth
– Price Performance

Ownership

Stock Price Performance

Crispidea Coverage

No of Pages: 35

To download the previous quarter’s equity report CLICK HERE

Follow our LinkedIn page for more updates